Literature DB >> 2354402

Epidermal growth factor receptor expression in 72 meningiomas.

N R Jones1, M L Rossi, M Gregoriou, J T Hughes.   

Abstract

The expression of epidermal growth factor receptor (EGF-R) was studied immunohistochemically in 72 meningiomas using two monoclonal antibodies with specificities to protein and carbohydrate components, respectively, of the external domain of the EGF-R. One third of the tumors had cytoplasmic and membrane positivity with the protein-specific antibody but in none were there positive tumor cells with the carbohydrate-specific antibody which recognizes the blood group A antigen. There was no difference in EGF-R expression between typical and aggressive meningiomas. No evidence was found to support previous reports of specific EGF-R immunoreactivity in the vascular endothelial cells of meningiomas. The authors believe this discrepancy to be due to detection of normal blood group A antigen attached to endothelial cells in patients of blood group A or AB. This occurs because many monoclonal anti-EGF-R antibodies are specific for A antigen which is found on the EGF-R of A431 cells but has not been reported on EGF-R elsewhere.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2354402     DOI: 10.1002/1097-0142(19900701)66:1<152::aid-cncr2820660127>3.0.co;2-5

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

1.  Assessment of Epidermal Growth Factor Receptor (EGFR) expression in human meningioma.

Authors:  A Gabriella Wernicke; Adam P Dicker; Michal Whiton; Jana Ivanidze; Terry Hyslop; Elizabeth H Hammond; Arie Perry; David W Andrews; Lawrence Kenyon
Journal:  Radiat Oncol       Date:  2010-05-30       Impact factor: 3.481

Review 2.  New prospects for management and treatment of inoperable and recurrent skull base meningiomas.

Authors:  Mahlon D Johnson; Burak Sade; Michael T Milano; Joung H Lee; Steven A Toms
Journal:  J Neurooncol       Date:  2007-07-12       Impact factor: 4.130

3.  Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.

Authors:  Andrew D Norden; Jeffrey J Raizer; Lauren E Abrey; Kathleen R Lamborn; Andrew B Lassman; Susan M Chang; W K Alfred Yung; Mark R Gilbert; Howard A Fine; Minesh Mehta; Lisa M Deangelis; Timothy F Cloughesy; H Ian Robins; Kenneth Aldape; Janet Dancey; Michael D Prados; Frank Lieberman; Patrick Y Wen
Journal:  J Neurooncol       Date:  2009-06-28       Impact factor: 4.130

Review 4.  Pathogenesis of peri-tumoral edema in intracranial meningiomas.

Authors:  Moncef Berhouma; Timothee Jacquesson; Emmanuel Jouanneau; François Cotton
Journal:  Neurosurg Rev       Date:  2017-08-24       Impact factor: 3.042

Review 5.  The biology and pathology of selected skull base tumors.

Authors:  L Barnes; S B Kapadia
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

6.  Lovastatin is a potent inhibitor of meningioma cell proliferation: evidence for inhibition of a mitogen associated protein kinase.

Authors:  Mahlon D Johnson; Ann Woodard; Evelyn J Okediji; Steven A Toms; George S Allen
Journal:  J Neurooncol       Date:  2002-01       Impact factor: 4.130

Review 7.  Medical therapies for meningiomas.

Authors:  Patrick Y Wen; Eudocia Quant; Jan Drappatz; Rameen Beroukhim; Andrew D Norden
Journal:  J Neurooncol       Date:  2010-09-04       Impact factor: 4.130

8.  Expression of PDGF, PDGF-receptor, EGF-receptor and sex hormone receptors on meningioma.

Authors:  J I Kuratsu; H Seto; M Kochi; Y Ushio
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

Review 9.  Medical management of meningiomas.

Authors:  Wendy J Sherman; Jeff J Raizer
Journal:  CNS Oncol       Date:  2013-03

10.  Increased STAT-3 and synchronous activation of Raf-1-MEK-1-MAPK, and phosphatidylinositol 3-Kinase-Akt-mTOR pathways in atypical and anaplastic meningiomas.

Authors:  Mahlon D Johnson; Mary O'Connell; Fran Vito; Robert S Bakos
Journal:  J Neurooncol       Date:  2008-11-26       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.